Actual Medicinal Product (AMP) Zyprexa 2.5mg tablets (DE Pharmaceuticals)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.
- Provenance
-
Compatiblity recommendation derived from Eli Lilly and Accord Healthcare Ltd products.
- Generic
- Olanzapine
- Formulation
- Olanzapine 2.5mg tablets
-
Olanzapine
-
Olanzapine 2.5mg tablets
-
Zyprexa 2.5mg tablets (DE Pharmaceuticals)
-
-
Olanzapine 10mg oral lyophilisates sugar free
Olanzapine 5mg orodispersible tablets